The Lamira Nebulizer System, optimised for the administration of ARIKAYCE. Credit: PARI Pharma.

PARI Pharma has received authorisation for the Lamira Nebulizer System for delivery of Insmed’s drug product, ARIKAYCE (amikacin liposome inhalation suspension), in Japan.

The Lamira Nebulizer System has been specially optimised for administering ARIKAYCE.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug-specific eFlow Technology nebuliser system comprises a customised medication reservoir that can hold a full 8.4ml dose, a tailored aerosol head for the aerosolisation of ARIKAYCE and the valved aerosol chamber.

PARI Pharma president Dr Martin Knoch said: “Lamira enables us the ability to offer an eFlow Technology nebuliser to patients beyond Europe and North America.

“We are delighted that appropriate patients in Japan suffering from Nontuberculous mycobacterial (NTM) lung disease now have access to a new treatment option.”

Earlier this week, Japan’s Ministry of Health, Labour and Welfare (MHLW) granted approval for ARIKAYCE following approvals in the US and Europe.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A novel, inhaled, once-daily formulation of amikacin, ARIKAYCE is claimed to be the first inhaled liposomal dispersion approved by the MHLW.

It is also claimed to be the only therapy in Japan for treating patients with NTM lung disease caused by Mycobacterium avium complex (MAC) who have not responded to a previous multidrug regimen treatment.

Insmed Japan general manager Yuji Orihara said: “We are pleased that our valuable partnership with PARI has enabled us to bring to market the first approved drug, ARIKAYCE, to be used with the LAMIRA nebuliser device specifically for the treatment of patients in Japan with refractory MAC lung disease.”

eFlow Technology is an aerosol delivery platform that aids in the effective nebulisation of liquid medications through a vibrating, perforated membrane.